Background: Hydroxychloroquine (HCQ) is extensively utilized for the management of Systemic lupus erythematosus (SLE). HCQ retinopathy is a known and well-documented adverse impact of HCQ. This condition can be examined by optical coherence tomography angiography (OCTA).
Aim of the study: To evaluate central macular thickness on OCTA in SLE patients who are receiving HCQ.
Subjects and Methods: This study is an observational cross-sectional study that covered the right eyes of 90 individuals with systemic lupus erythematosus (SLE), which were divided into three groups. Group 1 consists of 30 patients who are not getting hydroxychloroquine (HCQ). Group 2 consists of 30 patients who were administered HCQ for a duration of less than 2 years. Group 3 consists of 30 patients who were administered HCQ for a duration exceeding 2 years. OCTA was conducted on all patients utilizing (Optovue, Inc., Fremont, CA, USA).
Results: There was no statistical significant difference with p-value >0.05 between study groups regarding central macular thickness. There was no statistical significant correlation with p-value >0.05 between HCQ treatment duration and macular thickness.
Conclusion: The central macular thickness in SLE patients on HCQ therapy utilizing OCTA did not show any notable alterations.